- Home
- AARD vs BARK Comparison
AARD vs BARK Comparison
Compare AARD & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- BARK
- Stock Information
- Founded
- AARD 2017
- BARK 2011
- Country
- AARD United States
- BARK United States
- Employees
- AARD N/A
- BARK N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- BARK Department/Specialty Retail Stores
- Sector
- AARD Health Care
- BARK Consumer Discretionary
- Exchange
- AARD Nasdaq
- BARK Nasdaq
- Market Cap
- AARD 242.9M
- BARK 244.9M
- IPO Year
- AARD 2025
- BARK N/A
- Fundamental
- Price
- AARD $8.59
- BARK $0.90
- Analyst Decision
- AARD Strong Buy
- BARK Strong Buy
- Analyst Count
- AARD 5
- BARK 3
- Target Price
- AARD $32.60
- BARK $2.50
- AVG Volume (30 Days)
- AARD 77.3K
- BARK 709.6K
- Earning Date
- AARD 08-13-2025
- BARK 08-07-2025
- Dividend Yield
- AARD N/A
- BARK N/A
- EPS Growth
- AARD N/A
- BARK N/A
- EPS
- AARD N/A
- BARK N/A
- Revenue
- AARD N/A
- BARK $470,831,000.00
- Revenue This Year
- AARD N/A
- BARK N/A
- Revenue Next Year
- AARD N/A
- BARK $6.25
- P/E Ratio
- AARD N/A
- BARK N/A
- Revenue Growth
- AARD N/A
- BARK N/A
- 52 Week Low
- AARD $4.88
- BARK $0.77
- 52 Week High
- AARD $19.58
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- BARK 54.79
- Support Level
- AARD N/A
- BARK $0.79
- Resistance Level
- AARD N/A
- BARK $0.92
- Average True Range (ATR)
- AARD 0.00
- BARK 0.04
- MACD
- AARD 0.00
- BARK 0.01
- Stochastic Oscillator
- AARD 0.00
- BARK 69.17
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.